ABBOTT LABORATORIES Amortization of Intangible Assets
ABBOTT LABORATORIES (ABT) reported Amortization of Intangible Assets of $422.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-04-29
- ABBOTT LABORATORIES amortization of intangible assets for the quarter ending 2026-03-31 was $422.00M, a 0.48% increase year-over-year.
- ABBOTT LABORATORIES amortization of intangible assets for the quarter ending 2025-12-31 was $422.00M, a 9.25% decline year-over-year.
- ABBOTT LABORATORIES amortization of intangible assets for the quarter ending 2025-09-30 was $420.00M, a 10.64% decline year-over-year.
- ABBOTT LABORATORIES amortization of intangible assets for the quarter ending 2025-06-30 was $420.00M, a 10.83% decline year-over-year.
- ABBOTT LABORATORIES amortization of intangible assets for fiscal 2025 was $1.68B, a 10.44% decline from fiscal 2024.
- ABBOTT LABORATORIES amortization of intangible assets for fiscal 2024 was $1.88B, a 4.48% decline from fiscal 2023.
- ABBOTT LABORATORIES amortization of intangible assets for fiscal 2023 was $1.97B, a 2.33% decline from fiscal 2022.
- ABBOTT LABORATORIES amortization of intangible assets for fiscal 2022 was $2.01B, a 1.66% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $422.00M 10-Q · filed 2026-04-29 | $844.00M derived: sum of 2 quarters · filed 2026-04-29 | $1.26B derived: sum of 3 quarters · filed 2026-04-29 | $1.68B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-12-31 | $422.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $842.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.26B derived: sum of 3 quarters · filed 2026-02-20 | $1.68B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $420.00M 10-Q · filed 2025-10-29 | $840.00M derived: sum of 2 quarters · filed 2025-10-29 | $1.26B 10-Q · filed 2025-10-29 | $1.73B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-06-30 | $420.00M 10-Q · filed 2025-07-30 | $840.00M 10-Q · filed 2025-07-30 | $1.30B derived: sum of 3 quarters · filed 2026-04-29 | $1.77B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-03-31 | $420.00M 10-Q · filed 2026-04-29 | $885.00M derived: sum of 2 quarters · filed 2026-04-29 | $1.35B derived: sum of 3 quarters · filed 2026-04-29 | $1.83B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $465.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $935.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.41B derived: sum of 3 quarters · filed 2026-02-20 | $1.88B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $470.00M 10-Q · filed 2025-10-29 | $941.00M derived: sum of 2 quarters · filed 2025-10-29 | $1.41B 10-Q · filed 2025-10-29 | $1.89B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $471.00M 10-Q · filed 2025-07-30 | $943.00M 10-Q · filed 2025-07-30 | $1.42B derived: sum of 3 quarters · filed 2026-02-20 | $1.92B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $472.00M 10-Q · filed 2025-04-30 | $953.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.45B derived: sum of 3 quarters · filed 2026-02-20 | $1.95B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $481.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $977.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.48B derived: sum of 3 quarters · filed 2026-02-20 | $1.97B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $496.00M 10-Q · filed 2024-10-31 | $994.00M derived: sum of 2 quarters · filed 2024-10-31 | $1.49B 10-Q · filed 2024-10-31 | $1.98B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $498.00M 10-Q · filed 2024-07-31 | $989.00M 10-Q · filed 2024-07-31 | $1.49B derived: sum of 3 quarters · filed 2025-02-21 | $1.98B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $491.00M 10-Q · filed 2024-05-02 | $987.00M derived: sum of 2 quarters · filed 2025-02-21 | $1.49B derived: sum of 3 quarters · filed 2025-02-21 | $1.99B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $496.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $994.00M derived: sum of 2 quarters · filed 2025-02-21 | $1.50B derived: sum of 3 quarters · filed 2025-02-21 | $2.01B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $498.00M 10-Q · filed 2023-11-01 | $1.00B derived: sum of 2 quarters · filed 2023-11-01 | $1.52B 10-Q · filed 2023-11-01 | $2.03B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-06-30 | $507.00M 10-Q · filed 2023-08-03 | $1.02B 10-Q · filed 2023-08-03 | $1.53B derived: sum of 3 quarters · filed 2024-02-16 | $2.05B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-03-31 | $512.00M 10-Q · filed 2023-05-04 | $1.03B derived: sum of 2 quarters · filed 2024-02-16 | $1.55B derived: sum of 3 quarters · filed 2024-02-16 | $2.05B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2021-12-31 | $514.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $1.03B derived: sum of 2 quarters · filed 2024-02-16 | $1.54B derived: sum of 3 quarters · filed 2024-02-16 | $2.05B 10-K · filed 2024-02-16 | ||||
| 2021-09-30 | $520.00M 10-Q · filed 2022-11-01 | $1.02B derived: sum of 2 quarters · filed 2022-11-01 | $1.53B 10-Q · filed 2022-11-01 | $2.04B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $504.00M 10-Q · filed 2022-08-02 | $1.01B 10-Q · filed 2022-08-02 | $1.52B derived: sum of 3 quarters · filed 2023-02-17 | $2.03B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $509.00M 10-Q · filed 2022-05-03 | $1.02B derived: sum of 2 quarters · filed 2023-02-17 | $1.53B derived: sum of 3 quarters · filed 2023-02-17 | $2.08B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $508.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $1.02B derived: sum of 2 quarters · filed 2023-02-17 | $1.57B derived: sum of 3 quarters · filed 2023-02-17 | $2.13B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $510.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.06B derived: sum of 2 quarters · filed 2021-11-03 | $1.62B 10-Q · filed 2021-11-03 | $2.11B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $553.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.11B 10-Q · filed 2021-08-04 | $1.60B derived: sum of 3 quarters · filed 2022-02-18 | $2.08B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $561.00M 10-Q · filed 2021-05-05 | $1.04B derived: sum of 2 quarters · filed 2022-02-18 | $1.53B derived: sum of 3 quarters · filed 2022-02-18 | $2.01B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $483.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $967.00M derived: sum of 2 quarters · filed 2022-02-18 | $1.45B derived: sum of 3 quarters · filed 2022-02-18 | $1.94B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $484.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $967.00M derived: sum of 2 quarters · filed 2020-11-04 | $1.45B 10-Q · filed 2020-11-04 | $1.94B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $483.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $969.00M 10-Q · filed 2020-07-29 | $1.46B derived: sum of 3 quarters · filed 2021-02-19 | $2.00B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $486.00M 10-Q · filed 2020-04-29 | $974.00M derived: sum of 2 quarters · filed 2021-02-19 | $1.52B derived: sum of 3 quarters · filed 2021-02-19 | $2.08B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | $488.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $1.03B derived: sum of 2 quarters · filed 2021-02-19 | $1.59B derived: sum of 3 quarters · filed 2021-02-19 | $2.18B 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $544.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $1.11B derived: sum of 2 quarters · filed 2019-10-31 | $1.69B 10-Q · filed 2019-10-31 | $2.25B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $562.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $1.15B 10-Q · filed 2019-07-31 | $1.71B derived: sum of 3 quarters · filed 2020-02-21 | $2.21B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $584.00M 10-Q · filed 2019-05-01 | $1.14B derived: sum of 2 quarters · filed 2020-02-21 | $1.65B derived: sum of 3 quarters · filed 2020-02-21 | $2.04B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | $560.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.06B derived: sum of 2 quarters · filed 2020-02-21 | $1.45B derived: sum of 3 quarters · filed 2020-02-21 | $1.98B 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $501.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $893.00M derived: sum of 2 quarters · filed 2018-10-31 | $1.42B 10-Q · filed 2018-10-31 | $1.54B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $392.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $914.00M 10-Q · filed 2018-08-01 | $1.03B derived: sum of 3 quarters · filed 2019-02-22 | $1.18B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $522.00M 10-Q · filed 2018-05-02 | $643.00M derived: sum of 2 quarters · filed 2019-02-22 | $783.00M derived: sum of 3 quarters · filed 2019-02-22 | $928.00M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $121.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $261.00M derived: sum of 2 quarters · filed 2019-02-22 | $406.00M derived: sum of 3 quarters · filed 2019-02-22 | $550.00M 10-K · filed 2019-02-22 | ||||
| 2016-09-30 | $140.00M 10-Q · filed 2016-11-03 | $285.00M derived: sum of 2 quarters · filed 2016-11-03 | $429.00M 10-Q · filed 2017-11-02 | $572.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $145.00M 10-Q · filed 2016-08-03 | $289.00M 10-Q · filed 2017-08-02 | $432.00M derived: sum of 3 quarters · filed 2018-02-16 | $583.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $144.00M 10-Q · filed 2017-05-03 | $287.00M derived: sum of 2 quarters · filed 2018-02-16 | $438.00M derived: sum of 3 quarters · filed 2018-02-16 | $589.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $143.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $294.00M derived: sum of 2 quarters · filed 2018-02-16 | $445.00M derived: sum of 3 quarters · filed 2018-02-16 | $601.00M 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $151.00M 10-Q · filed 2016-11-03 | $302.00M derived: sum of 2 quarters · filed 2016-11-03 | $458.00M 10-Q · filed 2016-11-03 | $624.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $151.00M 10-Q · filed 2016-08-03 | $307.00M 10-Q · filed 2016-08-03 | $473.00M derived: sum of 3 quarters · filed 2017-02-17 | $602.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $156.00M 10-Q · filed 2016-05-04 | $322.00M derived: sum of 2 quarters · filed 2017-02-17 | $451.00M derived: sum of 3 quarters · filed 2017-02-17 | $612.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $166.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $295.00M derived: sum of 2 quarters · filed 2017-02-17 | $456.00M derived: sum of 3 quarters · filed 2017-02-17 | $630.00M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $129.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $290.00M derived: sum of 2 quarters · filed 2015-11-05 | $464.00M 10-Q · filed 2015-11-05 | $662.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $161.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $335.00M 10-Q · filed 2015-08-04 | $533.00M derived: sum of 3 quarters · filed 2016-02-19 | $730.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $174.00M 10-Q · filed 2015-05-06 | $372.00M derived: sum of 2 quarters · filed 2016-02-19 | $569.00M derived: sum of 3 quarters · filed 2016-02-19 | $766.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | $198.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $395.00M derived: sum of 2 quarters · filed 2016-02-19 | $592.00M derived: sum of 3 quarters · filed 2016-02-19 | $791.00M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $197.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $394.00M derived: sum of 2 quarters · filed 2014-11-06 | $593.00M 10-Q · filed 2014-11-06 | $593.07M 10-Q · filed 2013-11-07 | $923.01M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-06-30 | $197.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $396.00M 10-Q · filed 2014-08-05 | $396.31M 10-Q · filed 2013-08-06 | $726.01M derived: sum of 3 quarters · filed 2015-02-27 | $1.06B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-03-31 | $199.00M 10-Q · filed 2014-05-07 | $199.42M 10-Q · filed 2013-05-08 | $529.01M derived: sum of 2 quarters · filed 2015-02-27 | $858.39M derived: sum of 3 quarters · filed 2015-02-27 | $1.23B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $330.01M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $659.39M derived: sum of 2 quarters · filed 2015-02-27 | $1.03B derived: sum of 3 quarters · filed 2015-02-27 | $1.42B 10-K · filed 2015-02-27 | $1.42B 10-K · filed 2013-02-15 | |||
| 2012-09-30 | $329.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $699.93M derived: sum of 2 quarters · filed 2013-11-07 | $1.09B 10-Q · filed 2013-11-07 | $1.50B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2012-06-30 | $370.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $759.61M 10-Q · filed 2013-08-06 | $1.17B derived: sum of 3 quarters · filed 2014-02-21 | $1.59B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2012-03-31 | $389.06M 10-Q · filed 2013-05-08 | $796.79M derived: sum of 2 quarters · filed 2014-02-21 | $1.21B derived: sum of 3 quarters · filed 2014-02-21 | $1.65B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2011-12-31 | $407.73M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $825.41M derived: sum of 2 quarters · filed 2014-02-21 | $1.26B derived: sum of 3 quarters · filed 2014-02-21 | $1.65B 10-K · filed 2014-02-21 | $1.65B 10-K · filed 2012-02-21 | |||
| 2011-09-30 | $417.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $849.72M derived: sum of 2 quarters · filed 2012-11-07 | $1.24B 10-Q · filed 2012-11-07 | $1.65B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $432.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $823.59M 10-Q · filed 2012-08-07 | $1.23B derived: sum of 3 quarters · filed 2013-02-15 | $1.59B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $391.55M 10-Q · filed 2012-05-08 | $797.89M derived: sum of 2 quarters · filed 2013-02-15 | $1.16B derived: sum of 3 quarters · filed 2013-02-15 | $1.53B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $406.35M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $770.21M derived: sum of 2 quarters · filed 2013-02-15 | $1.14B derived: sum of 3 quarters · filed 2013-02-15 | $1.42B 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $363.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $735.26M derived: sum of 2 quarters · filed 2011-11-04 | $1.01B 10-Q · filed 2011-11-04 | $1.23B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $371.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-04 | $646.64M 10-Q · filed 2011-08-04 | $869.38M derived: sum of 3 quarters · filed 2012-02-21 | $1.10B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $275.25M 10-Q · filed 2011-05-06 | $497.99M derived: sum of 2 quarters · filed 2012-02-21 | $726.48M derived: sum of 3 quarters · filed 2012-02-21 | $959.81M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $222.74M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $451.23M derived: sum of 2 quarters · filed 2012-02-21 | $684.56M derived: sum of 3 quarters · filed 2012-02-21 | $878.53M 10-K · filed 2012-02-21 | ||||
| 2009-09-30 | $228.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $461.82M derived: sum of 2 quarters · filed 2010-11-05 | $655.79M 10-Q · filed 2010-11-05 | $857.46M derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-06-30 | $233.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-05 | $427.30M 10-Q · filed 2010-08-05 | $628.98M derived: sum of 3 quarters · filed 2011-02-18 | $831.32M derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-03-31 | $193.97M 10-Q · filed 2010-05-04 | $395.64M derived: sum of 2 quarters · filed 2011-02-18 | $597.99M derived: sum of 3 quarters · filed 2011-02-18 | |||||
| 2008-12-31 | $201.67M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $404.01M derived: sum of 2 quarters · filed 2011-02-18 | $787.10M 10-K · filed 2011-02-18 | |||||
| 2008-09-30 | $202.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | $585.43M 10-Q · filed 2009-11-06 | ||||||
| 2008-06-30 | $383.09M 10-Q · filed 2009-08-07 | |||||||
| 2007-12-31 | $782.03M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |